Biocompatible ocular implants

• US 5,443,505 A
• Filed: 11/15/1993
• Issued: 08/22/1995
• Est. Priority Date: 11/15/1993
• Status: Expired due to Term

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Oculex Pharmaceuticals, Inc. (Abbvie Incorporated)
• Inventors: Wong, Vernon G., Kochinke, Frank
• Primary Examiner(s): SHAY, RANDY CITRIN
• Application Number:
  US08/153,184
• Time in Patent Office: 645 Days
• Field of Search: 623/4, 623/5, 604/294, 604/890.1, 604/891.1, 604/892.1, 424/426-429
• US Class Current: 623/4.1
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drags is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

Claims

1. A method for treating an eye condition which comprises:

preparing an implant by combining a physiologically active therapeutic agent and a permeability enhancing agent encapsulated in a pharmacologically acceptable biocompatible polymer; and

introducing said implant extrinsic to the vitreous and incapable of migration from an implantation site, wherein said site is characterized by being avascular, permitting diffusion of a physiologically active agent from said implant into the vitreous, and in proximity to said eye condition,

wherein said therapeutic agent is maintained at an effective dosage for said eye condition at the site of said eye condition for an extended period of time.

2. A method-according to claim 1, wherein said biocompatible polymer is non-biodegradable.

3. A method according to claim 2, wherein said polymer is a polyurethane.

4. A method according to claim 2, wherein said polymer is an ethylene vinyl ester copolymer.

5. A method according to claim 4, wherein said ethylene vinyl ester copolymer is ethylene vinyl acetate.

6. A method according to claim 1, wherein said introducing step comprises introducing said implant into a suprachoroidal space, where the sclera is cut to expose the suprachoroid.

7. A method according to claim 6, wherein said suprachoroidal space is a surgically induced avascular region.

8. A method according to claim 1, where said introducing step comprises introducing said implant into the avascular pars plana.

9. A method according to claim 1, wherein said agent is an antitumor agent.

10. A method according to claim 1, wherein said agent is a bacterial agent.

11. A method according to claim 1, wherein said agent is a drug.

13. A method according to claim 9, wherein said implant is a plaque or particles.

14. A method according to claim 13, wherein said permeability enhancing agent is selected from the group consisting of at least one of isopropyl myristate, ethanol or oleic acid.

12. A method for treating an eye condition which comprises:

preparing an implant by combining a physiologically active therapeutic agent and a permeability enhancing agent encapsulated in a pharmacologically acceptable biocompatible polymer; and

introducing into the avascular pars plana of an eye said implant incapable of migration from said pars plana, wherein one implantation site is characterized by permitting diffusion of a physiologically active agent from said implant into the vitreous, and in proximity to said eye condition,

wherein said agent is maintained at an effective dosage for said eye condition at the site of said eye condition for an extended period of time.

15. A method for treating choroidal tumors of an eye which comprises:

preparing an implant by combining an antitumor agent and a permeability enhancing agent encapsulated in a pharmacologically acceptable biocompatible polymer; and

introducing into an avascular region of a suprachoroidal space of said eye said implant incapable of migration from said space, wherein said implant provides an effective dosage of said antitumor agent over an extended period of time.

16. A method according to claim 15, wherein said implant is a plaque having length and width dimensions of about 0.5 to 10 mm×

0.5 to 10 mm with a thickness of about 0.25 to 10 mm.

17. A method according to claim 16, wherein said antitumor agent is a member of the group consisting of methotrexate, vincristine, or a bacterial agent.

18. A method according to claim 17, wherein said antitumor agent is a bacterial agent, which is acid-fast bacilli.

19. A method according to claim 17, wherein said antitumor agent is C. parvum.